New hope for tough blood cancers: RPT1G trial launches
NCT ID NCT07107126
First seen Mar 26, 2026 · Last updated May 15, 2026 · Updated 7 times
Summary
This early-stage study tests a new drug called RPT1G in 24 people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) that have not responded to standard treatments. The main goals are to check if the drug is safe and to find the best dose. This is not a cure trial; it aims to control the disease and gather safety information.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Conditions
Explore the condition pages connected to this study.